期刊文献+

利用基因工程技术构建人WWP2基因的真核表达载体

Construction of Wwp2 Gene Eukaryotic Expression Vector via Genetic Engineering Technology
下载PDF
导出
摘要 目的构建E3泛素连接酶WWP2基因的真核表达载体,并鉴定其表达。方法利用PCR扩增技术扩增人WWP2基因的编码序列,把WWP2基因插入酶切后的pc DNA3.1-Flag空载体,用PCR法、酶切法及基因测序的方法检测重组质粒的正确性,然后将所构建质粒pc DNA3.1-Flag-WWP2转染入人胚肾细胞HEK293T中,并利用免疫印记法检测其表达情况。结果 pc DNA3.1-Flag-WWP2真核表达载体构建成功,且能实现在HEK293T细胞中的表达。结论文章成功构建了带Flag标签的人WWP2真核表达载体,为后续的WWP2基因功能以及作为肺癌治疗新靶点的可行性研究奠定了基础。 Objective To construct a eukaryotic expression vector of E3 ubiquitin ligase WWP2 and to identify its expression.Method The coding sequence of human WWP2 gene was amplified by PCR,and then inserted into pcDNA3.1-Flag eukaryotic expression vector.After identification by PCR,restriction endonuclease analysis and sequencing,the recombinant plasmid pcDNA3.1-Flag-WWP2 was transfected into human HEK293T embryonic kidney cells,and western blotting was applied to detect the expression of WWP2 gene.Result The WWP2 gene expression sequence was successfully inserted into pcDNA3.1-Flag vector,and the recombinant vector could express in HEK293T cells detected by western blot.Conclusion Flag-tagged WWP2 gene eukaryotic expression vector was successfully constructed,laying a solid foundation for the further study of WWP2 function in cancer.
作者 雷子宸 刘姿 马亮 LEI Zichen;LIU zi;MA Liang(Maanshan Secondary School;School of Chemistry and Chemical Engineering, Anhui Technology University,Maanshan,Anhui 243000,China)
出处 《九江学院学报(自然科学版)》 CAS 2018年第1期74-77,共4页 Journal of Jiujiang University:Natural Science Edition
基金 国家自然科学基金青年基金项目(编号81402511)的研究成果之一
关键词 WWP2 肺癌 基因工程 真核表达 WWP2 lung cancer genetic engineering eukaryotic expression
  • 相关文献

参考文献3

二级参考文献39

  • 1张光林,王钢胜,冯会.厄洛替尼治疗EGFR状态未知晚期肺腺癌的疗效观察[J].山东医药,2013,53(45):13-15. 被引量:3
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
  • 3Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Arch Pathol Lab Med, 2013, 137(6): 828-860.
  • 4Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 2010, 363 (18): 1734-1739.
  • 5Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res, 2011, 71(18): 6051-6060.
  • 6Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 2008, 8 (1): 11-23.
  • 7Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther, 2013, 95(1): 15-23.
  • 8Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci, 2008, 105(50): 19893-19897.
  • 9Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev, 2007, 21(24): 3214-3231.
  • 10Rikova K, Guo A, Zeng O~ et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131 (6): 1190-1203.

共引文献1017

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部